A Phase 3, Randomized, Double Blind, Placebo And Active‑Controlled, Multicenter, Parallel‑Group Study Of The Analgesic Efficacy And Safety Of Tanezumab In Adult Subjects With Chronic Low Back Pain

Trial Profile

A Phase 3, Randomized, Double Blind, Placebo And Active‑Controlled, Multicenter, Parallel‑Group Study Of The Analgesic Efficacy And Safety Of Tanezumab In Adult Subjects With Chronic Low Back Pain

Recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Aug 2017

At a glance

  • Drugs Tanezumab (Primary) ; Tramadol
  • Indications Back pain
  • Focus Registrational; Therapeutic Use
  • Acronyms TANGO
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Jul 2017 Planned primary completion date changed from 25 Oct 2017 to 17 Oct 2017.
    • 13 Jun 2017 According to a Pfizer media release, results from this study are expected in 2018.
    • 12 Jun 2017 Planned End Date changed from 17 Jan 2019 to 16 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top